Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
86 hedge funds and large institutions have $218M invested in Clearside Biomedical in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 17 closing their positions.
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
9% more funds holding
Funds holding: 79 → 86 (+7)
3% more capital invested
Capital invested by funds: $211M → $218M (+$7.21M)
0.15% more ownership
Funds ownership: 4.1% → 4.25% (+0.15%)
44% less call options, than puts
Call options by funds: $885K | Put options by funds: $1.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$9.17M |
| 2 |
BlackRock
New York
|
+$7.25M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$4.47M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.25M |
| 5 |
Man Group
London,
United Kingdom
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.65M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$3.26M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.21M |
| 4 |
Millennium Management
New York
|
-$1.7M |
| 5 |
JP Morgan Chase
New York
|
-$1.21M |
CLSD Hedge Fund Activity: Q2 2018 in Review
86 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2018, worth a combined $218M — up 3.4% from $211M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CLSD positions and 17 closed out — a net gain of 7 holders — while 28 added to existing stakes and 23 trimmed.
The largest buyer was Northpointe Capital, opening a new position worth an estimated $9.17M. The largest seller was Cormorant Asset Management, cutting an estimated $7.65M.
- 86 institutional investors held Clearside Biomedical (CLSD) as of Q2 2018, up from 79 in Q1 2018.
- Funds reported $218M of Clearside Biomedical stock for Q2 2018, up 3.4% quarter-over-quarter.
- 24 funds opened new Clearside Biomedical positions in Q2 2018 and 17 closed out, a net change of +7 holders.
- The largest Clearside Biomedical buyer in Q2 2018 was Northpointe Capital, an estimated $9.17M added.
- The largest Clearside Biomedical seller in Q2 2018 was Cormorant Asset Management, an estimated $7.65M sold.
Based on aggregated 13F filings for Q2 2018.